653 related articles for article (PubMed ID: 26538627)
1. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
3. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
5. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea.
Seo GH; Cho YY; Chung JH; Kim SW
Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388
[TBL] [Abstract][Full Text] [Related]
6. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
7. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
9. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
[TBL] [Abstract][Full Text] [Related]
10. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
Hisada M; Chen BE; Jaffe ES; Travis LB
J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
12. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
Lin CY; Lin CL; Huang WS; Kao CH
J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
[TBL] [Abstract][Full Text] [Related]
13. Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer.
Ahn HY; Min HS; Yeo Y; Ma SH; Hwang Y; An JH; Choi HS; Keam B; Im SA; Park DJ; Park IA; Noh DY; Youn YK; Chung JK; Cho BY; Park SK; Park YJ
J Clin Endocrinol Metab; 2015 Sep; 100(9):3486-93. PubMed ID: 26147607
[TBL] [Abstract][Full Text] [Related]
14. Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
Wu GX; Nelson RA; Kim JY; Raz DJ
Clin Lung Cancer; 2017 Sep; 18(5):543-550.e3. PubMed ID: 28412093
[TBL] [Abstract][Full Text] [Related]
15. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
[TBL] [Abstract][Full Text] [Related]
16. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
17. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.
Chaturvedi AK; Engels EA; Gilbert ES; Chen BE; Storm H; Lynch CF; Hall P; Langmark F; Pukkala E; Kaijser M; Andersson M; Fosså SD; Joensuu H; Boice JD; Kleinerman RA; Travis LB
J Natl Cancer Inst; 2007 Nov; 99(21):1634-43. PubMed ID: 17971527
[TBL] [Abstract][Full Text] [Related]
18. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Ku FC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1995-2004. PubMed ID: 25971624
[TBL] [Abstract][Full Text] [Related]
19. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
20. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
